EXEL News and Press, Exelixis Inc. From 09/15/22

Summary Performance has been poor over the past five years even as executive compensation remains on the high end. Cabozantinib continues to show promising sales growth and retention of market share in key indications such as renal cell carcinoma. Partnering efforts focus on n...

– Both single-agent XL092 and XL092 in combination with atezolizumab demonstrated encouraging efficacy and safety in a heavily pretreated patient population – – XL092 demonstrated preliminary clinical activity similar to that observed...

Summary Return on equity (ROE) may help to reveal profitable firms, but does Wall Street reward the stock prices of these firms? Warren Buffett considers it a positive sign when a company is able to earn above-average returns on equity. Return on equity can be simply stated as...

– Cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab – – Median progression-free survival was not yet reached with the com...

– Presentations to be webcast on www.exelixis.com – Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company’s management team will participate in fireside chats at the following investor conferences in September: Morgan Stanle...

Cancer-focused biotech Exelixis, Inc. ( NASDAQ: EXEL ) has filed another court case against Israeli drugmaker Teva Pharmaceutical Industries ( TEVA ) on allegations of patent infringement related to a generic version of the company’s kidney cancer therapy Cabometyx....

It can be scary to put your hard-earned money into a bear market. But it is the right time for growth-oriented investors with a long-term horizon to pounce. Interestingly, there are some stocks, such as biotech companies Exelixis (NASDAQ: EXEL) and Bristol-Myers Squibb (NYSE: ...

A solid earnings beat for Q2 2022 was not enough to lift the Exelixis ( EXEL ) shares on Wednesday as the cancer-focused biotech lost ~7% , the highest intraday decline since May. The Cabometyx kidney cancer drug maker reported $419.3M in revenue for the quarter, beating S...

Image source: The Motley Fool. Exelixis (NASDAQ: EXEL) Q2 2022 Earnings Call Aug 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis (EXEL) Q2 2022 Earnings Call Transcript

Exelixis, Inc. (EXEL) Q2 2022 Earnings Conference Call August 09, 2022, 17:00 ET Company Participants Susan Hubbard - EVP, Public Affairs & IR Michael Morrissey - CEO, President & Director Christopher Senner - EVP & CFO Patrick Haley - EVP, Commer...